Bladder cancer is the ninth most prevalent cancer globally and the fifth most common cancer among men.
Almost 3,000 people diagnosed in Australia every year and 75,000 new cases in the US annually.
If detected early, bladder cancer is treatable but it has one of the highest recurrence rates of all cancers, requiring regular monitoring.
TOLMAR Australia is a specialised uro-oncology organisation, providing medicines and support to those with advanced prostate cancer and fertility issues. We have strong working relationships with urologists to explore progressive approaches to treatment and care.
In line with TOLMAR's vision, and support of progressive approaches to urological cancer management and treatment, our strategic commercial partnership with Pacific Edge Limited gives us the ability to deliver products and support to those being investigated or treated for bladder cancer.
Using this link will let you leave www.tolmar.com.au, therefore the information may not comply with the Australian or New Zealand regulatory authority environment. Any information provided by this source should be discussed with your healthcare professional and does not replace their advice. This link is provided to you only as information, not as advice, and the inclusion of this link does not imply endorsement by TOLMAR.Continue